| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 57 | 2024 | 2159 | 6.330 |
Why?
|
| Cardiovascular Diseases | 26 | 2024 | 1795 | 3.880 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 30 | 2014 | 144 | 3.320 |
Why?
|
| Muscle, Smooth, Vascular | 14 | 2016 | 455 | 3.020 |
Why?
|
| Hypoglycemic Agents | 24 | 2023 | 1031 | 2.840 |
Why?
|
| Mitochondria, Muscle | 8 | 2021 | 97 | 2.630 |
Why?
|
| Insulin Resistance | 29 | 2024 | 1167 | 2.390 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 939 | 2.190 |
Why?
|
| Mitochondria | 11 | 2022 | 785 | 1.970 |
Why?
|
| Blood Vessels | 5 | 2018 | 187 | 1.850 |
Why?
|
| Endothelium, Vascular | 12 | 2022 | 890 | 1.840 |
Why?
|
| Insulin | 27 | 2023 | 2157 | 1.750 |
Why?
|
| Diabetic Angiopathies | 10 | 2017 | 261 | 1.650 |
Why?
|
| Aorta | 9 | 2018 | 364 | 1.650 |
Why?
|
| Exercise | 22 | 2022 | 1647 | 1.610 |
Why?
|
| Microcirculation | 7 | 2018 | 152 | 1.570 |
Why?
|
| Metformin | 6 | 2022 | 293 | 1.540 |
Why?
|
| Exercise Tolerance | 9 | 2024 | 234 | 1.480 |
Why?
|
| Microvessels | 4 | 2018 | 73 | 1.440 |
Why?
|
| Adaptation, Physiological | 6 | 2021 | 501 | 1.410 |
Why?
|
| Thiazolidinediones | 11 | 2021 | 146 | 1.390 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2016 | 236 | 1.370 |
Why?
|
| Muscle, Skeletal | 17 | 2023 | 1515 | 1.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2022 | 3358 | 1.260 |
Why?
|
| Glucose | 13 | 2022 | 940 | 1.230 |
Why?
|
| Models, Cardiovascular | 3 | 2017 | 179 | 1.200 |
Why?
|
| Vascular Stiffness | 5 | 2023 | 425 | 1.150 |
Why?
|
| Catechin | 3 | 2022 | 26 | 1.150 |
Why?
|
| Blood Glucose | 21 | 2024 | 1936 | 1.140 |
Why?
|
| Metabolic Syndrome | 9 | 2019 | 392 | 1.130 |
Why?
|
| Hyperglycemia | 4 | 2017 | 313 | 1.130 |
Why?
|
| Rats | 36 | 2023 | 5339 | 1.100 |
Why?
|
| Oxygen Consumption | 18 | 2021 | 585 | 1.060 |
Why?
|
| Oxidative Stress | 11 | 2022 | 1167 | 1.050 |
Why?
|
| Diabetic Neuropathies | 2 | 2023 | 78 | 1.050 |
Why?
|
| Glucose Intolerance | 2 | 2024 | 139 | 1.050 |
Why?
|
| Obesity | 17 | 2023 | 2715 | 1.030 |
Why?
|
| Glucagon-Like Peptide 1 | 6 | 2020 | 103 | 1.010 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2020 | 198 | 1.000 |
Why?
|
| Oxygen | 3 | 2018 | 854 | 1.000 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2021 | 74 | 0.920 |
Why?
|
| Oxidative Phosphorylation | 5 | 2021 | 156 | 0.920 |
Why?
|
| Hypertension | 5 | 2022 | 1199 | 0.900 |
Why?
|
| Humans | 121 | 2024 | 118251 | 0.880 |
Why?
|
| Drug Design | 1 | 2023 | 158 | 0.860 |
Why?
|
| Sex Factors | 7 | 2022 | 1765 | 0.850 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2019 | 39 | 0.840 |
Why?
|
| Vascular Diseases | 2 | 2022 | 241 | 0.840 |
Why?
|
| Insulins | 1 | 2022 | 34 | 0.830 |
Why?
|
| Animals | 66 | 2023 | 33152 | 0.760 |
Why?
|
| Rats, Wistar | 6 | 2023 | 396 | 0.730 |
Why?
|
| Cardiovascular System | 3 | 2024 | 127 | 0.720 |
Why?
|
| Physical Conditioning, Animal | 3 | 2018 | 204 | 0.720 |
Why?
|
| Blood Flow Velocity | 6 | 2018 | 327 | 0.720 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2016 | 211 | 0.710 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2020 | 94 | 0.700 |
Why?
|
| Fatty Acids, Nonesterified | 6 | 2016 | 162 | 0.680 |
Why?
|
| Motor Activity | 3 | 2015 | 664 | 0.680 |
Why?
|
| Pterins | 1 | 2018 | 8 | 0.670 |
Why?
|
| Adipocytes | 7 | 2001 | 195 | 0.640 |
Why?
|
| Leadership | 1 | 2021 | 310 | 0.630 |
Why?
|
| Male | 61 | 2023 | 57474 | 0.620 |
Why?
|
| Women's Health | 3 | 2020 | 274 | 0.610 |
Why?
|
| Vasodilation | 7 | 2022 | 456 | 0.610 |
Why?
|
| Sex Characteristics | 9 | 2023 | 667 | 0.610 |
Why?
|
| Arterioles | 2 | 2016 | 46 | 0.590 |
Why?
|
| Atherosclerosis | 3 | 2011 | 345 | 0.590 |
Why?
|
| Carotid Arteries | 1 | 2018 | 184 | 0.590 |
Why?
|
| Cell Division | 7 | 2009 | 775 | 0.580 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 44 | 0.570 |
Why?
|
| Metabolomics | 2 | 2020 | 540 | 0.570 |
Why?
|
| Hemorheology | 1 | 2016 | 20 | 0.570 |
Why?
|
| Glycocalyx | 1 | 2016 | 23 | 0.560 |
Why?
|
| Nitric Oxide | 3 | 2022 | 891 | 0.550 |
Why?
|
| Capillaries | 1 | 2016 | 102 | 0.540 |
Why?
|
| Diabetes Complications | 2 | 2020 | 218 | 0.540 |
Why?
|
| Needs Assessment | 1 | 2018 | 325 | 0.540 |
Why?
|
| Epidemics | 4 | 2023 | 70 | 0.540 |
Why?
|
| Models, Biological | 4 | 2020 | 1701 | 0.530 |
Why?
|
| Female | 59 | 2023 | 61261 | 0.520 |
Why?
|
| Adamantane | 1 | 2015 | 16 | 0.520 |
Why?
|
| Software | 2 | 2018 | 566 | 0.520 |
Why?
|
| Cell Respiration | 3 | 2020 | 76 | 0.510 |
Why?
|
| Dipeptides | 1 | 2015 | 51 | 0.510 |
Why?
|
| Risk Factors | 16 | 2022 | 8958 | 0.510 |
Why?
|
| Regional Blood Flow | 7 | 2020 | 417 | 0.480 |
Why?
|
| Adipose Tissue | 6 | 2021 | 595 | 0.470 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 39 | 0.460 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 27 | 0.450 |
Why?
|
| Biomedical Research | 2 | 2018 | 600 | 0.450 |
Why?
|
| Overweight | 3 | 2023 | 492 | 0.440 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 3676 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2005 | 225 | 0.420 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 493 | 0.410 |
Why?
|
| Adolescent | 26 | 2023 | 18364 | 0.410 |
Why?
|
| Tetrazoles | 1 | 2011 | 32 | 0.410 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2011 | 13 | 0.400 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 709 | 0.400 |
Why?
|
| Hyperinsulinism | 5 | 2019 | 107 | 0.390 |
Why?
|
| Glucose Tolerance Test | 3 | 2024 | 361 | 0.390 |
Why?
|
| Pulse Wave Analysis | 5 | 2023 | 216 | 0.390 |
Why?
|
| Endothelial Cells | 1 | 2016 | 717 | 0.380 |
Why?
|
| Phosphorylation | 16 | 2013 | 1622 | 0.380 |
Why?
|
| Signal Transduction | 8 | 2022 | 4688 | 0.380 |
Why?
|
| Exercise Therapy | 3 | 2022 | 355 | 0.370 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2009 | 618 | 0.370 |
Why?
|
| Cell Nucleus | 6 | 2016 | 577 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 5 | 2003 | 1157 | 0.360 |
Why?
|
| Hypoglycemia | 1 | 2014 | 401 | 0.360 |
Why?
|
| Cell Movement | 4 | 2011 | 888 | 0.360 |
Why?
|
| Hyperlipidemias | 3 | 2017 | 127 | 0.360 |
Why?
|
| Aging | 2 | 2018 | 1675 | 0.350 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 138 | 0.350 |
Why?
|
| Mentoring | 2 | 2022 | 101 | 0.350 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2021 | 44 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2013 | 2434 | 0.340 |
Why?
|
| Trans-Activators | 2 | 2001 | 373 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2000 | 285 | 0.330 |
Why?
|
| Sirtuin 3 | 2 | 2020 | 60 | 0.330 |
Why?
|
| Pulmonary Artery | 6 | 2013 | 1055 | 0.330 |
Why?
|
| Cells, Cultured | 14 | 2011 | 4044 | 0.310 |
Why?
|
| Superoxides | 2 | 2020 | 195 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 374 | 0.310 |
Why?
|
| Hemodynamics | 3 | 2021 | 1002 | 0.310 |
Why?
|
| Leg | 2 | 2021 | 234 | 0.300 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 964 | 0.290 |
Why?
|
| Citrate (si)-Synthase | 3 | 2021 | 49 | 0.290 |
Why?
|
| Echocardiography | 4 | 2020 | 556 | 0.290 |
Why?
|
| Vasoconstriction | 2 | 2018 | 212 | 0.290 |
Why?
|
| Nuclear Proteins | 2 | 2001 | 594 | 0.290 |
Why?
|
| Adult | 26 | 2022 | 31324 | 0.290 |
Why?
|
| Receptor, Insulin | 3 | 1996 | 100 | 0.290 |
Why?
|
| Cell Differentiation | 4 | 2004 | 1746 | 0.290 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 88 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 3 | 2021 | 44 | 0.280 |
Why?
|
| Incretins | 2 | 2017 | 15 | 0.280 |
Why?
|
| Glycation End Products, Advanced | 1 | 2006 | 67 | 0.270 |
Why?
|
| Peptide Fragments | 3 | 2021 | 700 | 0.270 |
Why?
|
| Biomarkers | 6 | 2023 | 3567 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2009 | 288 | 0.260 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 338 | 0.260 |
Why?
|
| Down-Regulation | 2 | 2010 | 623 | 0.260 |
Why?
|
| Pediatric Obesity | 3 | 2017 | 512 | 0.260 |
Why?
|
| Monosaccharide Transport Proteins | 4 | 2001 | 46 | 0.260 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 468 | 0.250 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 571 | 0.250 |
Why?
|
| Kinetics | 9 | 2017 | 1623 | 0.250 |
Why?
|
| Lipids | 4 | 2022 | 591 | 0.250 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 34 | 0.250 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 288 | 0.250 |
Why?
|
| Time Management | 1 | 2004 | 16 | 0.250 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 14 | 0.240 |
Why?
|
| Middle Aged | 19 | 2020 | 27510 | 0.240 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 46 | 0.230 |
Why?
|
| Double-Blind Method | 6 | 2019 | 1683 | 0.230 |
Why?
|
| Neurofilament Proteins | 1 | 2023 | 33 | 0.230 |
Why?
|
| Coronary Disease | 2 | 2003 | 355 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 87 | 0.230 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3156 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 418 | 0.220 |
Why?
|
| Life Style | 2 | 2023 | 431 | 0.220 |
Why?
|
| Brachial Artery | 3 | 2019 | 180 | 0.220 |
Why?
|
| Diastole | 2 | 2020 | 145 | 0.210 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2002 | 41 | 0.210 |
Why?
|
| Physical Fitness | 3 | 2013 | 179 | 0.210 |
Why?
|
| Sitagliptin Phosphate | 2 | 2019 | 30 | 0.210 |
Why?
|
| Transcription Factors | 6 | 2012 | 1567 | 0.210 |
Why?
|
| Ecdysterone | 1 | 2001 | 3 | 0.210 |
Why?
|
| Young Adult | 13 | 2021 | 10731 | 0.210 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 224 | 0.210 |
Why?
|
| Overnutrition | 1 | 2022 | 39 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2001 | 237 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 1 | 2022 | 226 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 127 | 0.200 |
Why?
|
| Exercise Test | 7 | 2016 | 552 | 0.200 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 63 | 0.200 |
Why?
|
| Faculty, Medical | 1 | 2004 | 252 | 0.200 |
Why?
|
| Cattle | 4 | 2009 | 974 | 0.200 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 422 | 0.200 |
Why?
|
| Age Factors | 3 | 2021 | 2990 | 0.190 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 248 | 0.190 |
Why?
|
| Muscle Contraction | 3 | 2017 | 413 | 0.190 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 173 | 0.190 |
Why?
|
| Triglycerides | 4 | 2013 | 515 | 0.190 |
Why?
|
| Glutathione | 1 | 2022 | 324 | 0.190 |
Why?
|
| Autophagy | 2 | 2016 | 312 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 143 | 0.190 |
Why?
|
| Antimycin A | 1 | 2020 | 13 | 0.190 |
Why?
|
| Protein Kinases | 2 | 2020 | 306 | 0.190 |
Why?
|
| Comorbidity | 3 | 2021 | 1516 | 0.190 |
Why?
|
| Glycopeptides | 1 | 2021 | 58 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 105 | 0.190 |
Why?
|
| Electron Transport Complex I | 1 | 2020 | 36 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 964 | 0.180 |
Why?
|
| Thrombosis | 2 | 2002 | 303 | 0.180 |
Why?
|
| Congresses as Topic | 2 | 2020 | 202 | 0.180 |
Why?
|
| Thinness | 3 | 2021 | 91 | 0.180 |
Why?
|
| Thiazoles | 2 | 2002 | 121 | 0.180 |
Why?
|
| Patient Participation | 1 | 2023 | 368 | 0.180 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 20 | 0.180 |
Why?
|
| Body Mass Index | 6 | 2018 | 2074 | 0.180 |
Why?
|
| Perfusion | 2 | 2018 | 152 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2010 | 274 | 0.180 |
Why?
|
| Mice | 18 | 2022 | 15446 | 0.180 |
Why?
|
| Fibroblasts | 4 | 2016 | 835 | 0.180 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1999 | 13 | 0.180 |
Why?
|
| Inservice Training | 1 | 2020 | 103 | 0.180 |
Why?
|
| Apoptosis | 3 | 2007 | 2461 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 410 | 0.170 |
Why?
|
| Oxidation-Reduction | 3 | 2020 | 935 | 0.170 |
Why?
|
| Cell Line | 8 | 2016 | 2693 | 0.170 |
Why?
|
| Aged | 14 | 2022 | 19594 | 0.170 |
Why?
|
| Transfection | 6 | 2007 | 887 | 0.170 |
Why?
|
| PPAR gamma | 3 | 2022 | 187 | 0.170 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 2 | 2021 | 9 | 0.170 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 94 | 0.170 |
Why?
|
| Deoxyglucose | 3 | 1993 | 46 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2022 | 340 | 0.170 |
Why?
|
| Microscopy, Video | 1 | 2018 | 27 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1433 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2022 | 9319 | 0.160 |
Why?
|
| Homocysteine | 1 | 2019 | 137 | 0.160 |
Why?
|
| Mentors | 1 | 2020 | 165 | 0.160 |
Why?
|
| Carbohydrates | 1 | 2018 | 58 | 0.160 |
Why?
|
| Venoms | 2 | 2016 | 33 | 0.160 |
Why?
|
| Bicycling | 2 | 2017 | 77 | 0.160 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2010 | 82 | 0.160 |
Why?
|
| Automation | 1 | 2018 | 76 | 0.160 |
Why?
|
| Hemoglobins | 3 | 2017 | 318 | 0.160 |
Why?
|
| Weight Gain | 1 | 2021 | 485 | 0.160 |
Why?
|
| Mitochondria, Heart | 1 | 2018 | 76 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 127 | 0.160 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 260 | 0.160 |
Why?
|
| Cysteine | 1 | 2019 | 184 | 0.160 |
Why?
|
| Glucose Clamp Technique | 4 | 2016 | 194 | 0.160 |
Why?
|
| Convection | 1 | 2017 | 7 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 1995 | 1343 | 0.160 |
Why?
|
| Serine | 5 | 2021 | 137 | 0.150 |
Why?
|
| Superoxide Dismutase | 3 | 2021 | 338 | 0.150 |
Why?
|
| Capillary Resistance | 1 | 2017 | 5 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 110 | 0.150 |
Why?
|
| Oxyhemoglobins | 1 | 2017 | 22 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2018 | 120 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1163 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2023 | 341 | 0.150 |
Why?
|
| Dietary Fats | 3 | 2023 | 323 | 0.150 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 41 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 160 | 0.150 |
Why?
|
| Diffusion | 1 | 2017 | 122 | 0.150 |
Why?
|
| United States | 9 | 2022 | 12488 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 246 | 0.150 |
Why?
|
| Ventricular Fibrillation | 1 | 2017 | 51 | 0.150 |
Why?
|
| Incidence | 2 | 2023 | 2413 | 0.150 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 33 | 0.150 |
Why?
|
| Albuminuria | 2 | 2020 | 196 | 0.150 |
Why?
|
| Heart Failure | 1 | 2010 | 1967 | 0.150 |
Why?
|
| Blood Pressure | 6 | 2021 | 1656 | 0.140 |
Why?
|
| Hypoxia | 4 | 2013 | 957 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 398 | 0.140 |
Why?
|
| Disease | 1 | 2017 | 87 | 0.140 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 468 | 0.140 |
Why?
|
| Leptin | 2 | 2017 | 228 | 0.140 |
Why?
|
| Blood Viscosity | 1 | 2016 | 17 | 0.140 |
Why?
|
| Adiponectin | 2 | 2016 | 224 | 0.140 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 53 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2022 | 465 | 0.140 |
Why?
|
| Swine, Miniature | 2 | 2013 | 70 | 0.140 |
Why?
|
| Luteinizing Hormone | 1 | 2017 | 173 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 4 | 2013 | 284 | 0.140 |
Why?
|
| Immediate-Early Proteins | 1 | 2016 | 54 | 0.140 |
Why?
|
| Menopause | 1 | 2019 | 266 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 808 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2016 | 650 | 0.140 |
Why?
|
| Pregnancy | 5 | 2022 | 5671 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 548 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 505 | 0.140 |
Why?
|
| Quality of Life | 2 | 2021 | 2355 | 0.140 |
Why?
|
| Chromans | 1 | 1995 | 20 | 0.140 |
Why?
|
| Forearm | 2 | 2015 | 117 | 0.140 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2017 | 216 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 2016 | 138 | 0.140 |
Why?
|
| Vascular Resistance | 1 | 2017 | 356 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 255 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2016 | 77 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2022 | 6443 | 0.130 |
Why?
|
| PC12 Cells | 3 | 2000 | 40 | 0.130 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2016 | 75 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 179 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 164 | 0.130 |
Why?
|
| Kidney | 4 | 2021 | 1351 | 0.130 |
Why?
|
| Islets of Langerhans | 4 | 2007 | 739 | 0.130 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 327 | 0.130 |
Why?
|
| Genes, Reporter | 4 | 2016 | 268 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 122 | 0.130 |
Why?
|
| Organelle Biogenesis | 1 | 2015 | 15 | 0.130 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 67 | 0.130 |
Why?
|
| Phosphates | 2 | 1993 | 166 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 734 | 0.130 |
Why?
|
| Swine | 4 | 2017 | 719 | 0.130 |
Why?
|
| Hyperandrogenism | 1 | 2015 | 14 | 0.130 |
Why?
|
| Adiposity | 2 | 2017 | 508 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 586 | 0.130 |
Why?
|
| Neurons | 1 | 2003 | 1340 | 0.130 |
Why?
|
| Ventricular Function | 1 | 2015 | 60 | 0.130 |
Why?
|
| Sleep | 1 | 2020 | 650 | 0.130 |
Why?
|
| Myocardium | 1 | 2020 | 965 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1994 | 57 | 0.120 |
Why?
|
| Child | 10 | 2021 | 19033 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2018 | 2664 | 0.120 |
Why?
|
| Body Composition | 5 | 2014 | 644 | 0.120 |
Why?
|
| American Heart Association | 1 | 2015 | 270 | 0.120 |
Why?
|
| Endothelium | 1 | 2015 | 116 | 0.120 |
Why?
|
| Cell Survival | 4 | 2009 | 1045 | 0.120 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 316 | 0.120 |
Why?
|
| CREB-Binding Protein | 3 | 2006 | 28 | 0.120 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 194 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3169 | 0.120 |
Why?
|
| Cyclic AMP | 3 | 2006 | 240 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2009 | 470 | 0.120 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2013 | 18 | 0.120 |
Why?
|
| Free Radical Scavengers | 2 | 2011 | 88 | 0.110 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 48 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 299 | 0.110 |
Why?
|
| Reaction Time | 1 | 2015 | 390 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2022 | 12929 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2017 | 554 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 84 | 0.110 |
Why?
|
| Uncoupling Protein 3 | 1 | 2012 | 10 | 0.110 |
Why?
|
| Prevalence | 1 | 2019 | 2321 | 0.110 |
Why?
|
| Rats, Mutant Strains | 1 | 2012 | 25 | 0.110 |
Why?
|
| Blotting, Western | 6 | 2011 | 1186 | 0.110 |
Why?
|
| Rats, Inbred SHR | 2 | 2010 | 42 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 566 | 0.110 |
Why?
|
| Peptides | 2 | 2016 | 879 | 0.110 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 156 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 4 | 2013 | 1784 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 1159 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2013 | 105 | 0.110 |
Why?
|
| Heterozygote | 1 | 2013 | 260 | 0.110 |
Why?
|
| Ion Channels | 1 | 2012 | 125 | 0.110 |
Why?
|
| Cytokines | 3 | 2012 | 1880 | 0.110 |
Why?
|
| Lymphocytosis | 1 | 1992 | 9 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 386 | 0.110 |
Why?
|
| Pituitary Diseases | 1 | 1992 | 23 | 0.100 |
Why?
|
| Enzyme Activation | 4 | 2010 | 810 | 0.100 |
Why?
|
| Hydrogen Peroxide | 2 | 2011 | 302 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 155 | 0.100 |
Why?
|
| 3T3 Cells | 4 | 2000 | 141 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 359 | 0.100 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 2435 | 0.100 |
Why?
|
| Rats, Inbred WKY | 4 | 2013 | 37 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2016 | 619 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 131 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2018 | 403 | 0.100 |
Why?
|
| Mitogens | 2 | 2009 | 57 | 0.090 |
Why?
|
| Casein Kinase II | 1 | 2010 | 21 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 352 | 0.090 |
Why?
|
| Placebos | 3 | 2019 | 202 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 107 | 0.090 |
Why?
|
| Longevity | 2 | 2022 | 150 | 0.090 |
Why?
|
| Receptors, LDL | 1 | 2010 | 40 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 284 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 4521 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1992 | 319 | 0.090 |
Why?
|
| Uracil | 1 | 2009 | 35 | 0.090 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2007 | 56 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 369 | 0.090 |
Why?
|
| Receptors, Glucagon | 1 | 2009 | 23 | 0.090 |
Why?
|
| Calcium | 2 | 1993 | 1151 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 52 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2006 | 2657 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 436 | 0.080 |
Why?
|
| Cardiac Output, Low | 1 | 2009 | 68 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2009 | 1322 | 0.080 |
Why?
|
| Diet | 4 | 2019 | 1143 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 1992 | 398 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2009 | 221 | 0.080 |
Why?
|
| Piperidines | 1 | 2009 | 171 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4887 | 0.080 |
Why?
|
| Heart | 2 | 2024 | 630 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 364 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2009 | 231 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2007 | 96 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1482 | 0.080 |
Why?
|
| Time Factors | 3 | 2014 | 6368 | 0.080 |
Why?
|
| Sequence Deletion | 2 | 1999 | 169 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 1992 | 447 | 0.070 |
Why?
|
| Fibrinolysis | 3 | 2003 | 127 | 0.070 |
Why?
|
| HIV Infections | 1 | 2021 | 2454 | 0.070 |
Why?
|
| Luciferases | 3 | 2005 | 142 | 0.070 |
Why?
|
| Perception | 1 | 2009 | 314 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 817 | 0.070 |
Why?
|
| Cholesterol | 2 | 2013 | 375 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2013 | 328 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2481 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 2477 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 1082 | 0.070 |
Why?
|
| Sports | 1 | 2009 | 191 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 403 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2006 | 34 | 0.070 |
Why?
|
| Oxidants | 2 | 2005 | 119 | 0.070 |
Why?
|
| Creatinine | 2 | 2020 | 491 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2013 | 2262 | 0.070 |
Why?
|
| Food Deprivation | 1 | 2006 | 24 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 139 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 360 | 0.070 |
Why?
|
| Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 206 | 0.060 |
Why?
|
| Fetus | 2 | 2021 | 690 | 0.060 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 131 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 681 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 304 | 0.060 |
Why?
|
| Fasting | 1 | 2005 | 256 | 0.060 |
Why?
|
| Olfactory Mucosa | 1 | 2004 | 59 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2004 | 89 | 0.060 |
Why?
|
| Anthracenes | 1 | 2003 | 29 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2017 | 217 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2003 | 35 | 0.060 |
Why?
|
| Rats, Zucker | 2 | 2017 | 34 | 0.060 |
Why?
|
| Sucrose | 1 | 2023 | 104 | 0.060 |
Why?
|
| Glucose Oxidase | 1 | 2003 | 20 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2004 | 345 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2855 | 0.060 |
Why?
|
| Bromocriptine | 1 | 2022 | 28 | 0.060 |
Why?
|
| Tyrosine | 1 | 2004 | 227 | 0.060 |
Why?
|
| Arteries | 2 | 2016 | 250 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 90 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2003 | 76 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 473 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2010 | 862 | 0.050 |
Why?
|
| Vitamin E | 1 | 2003 | 115 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 18 | 0.050 |
Why?
|
| Fetal Heart | 1 | 2022 | 29 | 0.050 |
Why?
|
| Regeneration | 1 | 2004 | 166 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 120 | 0.050 |
Why?
|
| Carnitine | 1 | 2022 | 65 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 247 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2021 | 57 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 913 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1681 | 0.050 |
Why?
|
| Parathyroid Hormone | 2 | 1993 | 99 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 194 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 267 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 52 | 0.050 |
Why?
|
| Arginine | 1 | 2003 | 247 | 0.050 |
Why?
|
| Base Sequence | 2 | 2009 | 2148 | 0.050 |
Why?
|
| Cell Death | 2 | 2016 | 336 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 394 | 0.050 |
Why?
|
| Respiration | 1 | 2022 | 184 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 122 | 0.050 |
Why?
|
| Hemoglobin, Sickle | 1 | 2021 | 16 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 456 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 347 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2022 | 167 | 0.050 |
Why?
|
| Heart Function Tests | 2 | 2013 | 61 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 175 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2021 | 198 | 0.050 |
Why?
|
| Medicare | 2 | 2022 | 664 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 409 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2016 | 394 | 0.050 |
Why?
|
| Poverty | 1 | 2004 | 444 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 3043 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 2855 | 0.050 |
Why?
|
| Placental Insufficiency | 1 | 2021 | 104 | 0.050 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 2 | 0.050 |
Why?
|
| Fatty Acid-Binding Protein 7 | 1 | 2000 | 3 | 0.050 |
Why?
|
| Phenylbutazone | 1 | 2020 | 2 | 0.050 |
Why?
|
| Tolbutamide | 1 | 2020 | 7 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 287 | 0.050 |
Why?
|
| Bucladesine | 1 | 2000 | 24 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 192 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2000 | 70 | 0.050 |
Why?
|
| Oxazoles | 1 | 2020 | 31 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 155 | 0.050 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2013 | 146 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2000 | 79 | 0.050 |
Why?
|
| Systole | 1 | 2020 | 168 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 45 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 62 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 30 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 817 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2021 | 1405 | 0.040 |
Why?
|
| Mutation | 2 | 2007 | 3435 | 0.040 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 32 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2001 | 218 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 746 | 0.040 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 2 | 0.040 |
Why?
|
| Proteins | 2 | 1996 | 935 | 0.040 |
Why?
|
| Macrophages | 1 | 2006 | 1311 | 0.040 |
Why?
|
| Chromogranins | 1 | 1999 | 13 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 154 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 334 | 0.040 |
Why?
|
| Sheep | 1 | 2021 | 762 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 162 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 174 | 0.040 |
Why?
|
| PPAR alpha | 2 | 2010 | 55 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 45 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 206 | 0.040 |
Why?
|
| Chromogranin A | 1 | 1999 | 40 | 0.040 |
Why?
|
| Pulmonary Circulation | 2 | 2013 | 423 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2018 | 68 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2010 | 34 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 321 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 69 | 0.040 |
Why?
|
| Phenylephrine | 1 | 2018 | 85 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 236 | 0.040 |
Why?
|
| Diet, Western | 1 | 2018 | 69 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 418 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 541 | 0.040 |
Why?
|
| Hippocampus | 1 | 2003 | 735 | 0.040 |
Why?
|
| Hematocrit | 1 | 2018 | 89 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 192 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2020 | 233 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2018 | 143 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 1072 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 343 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 714 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 133 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 149 | 0.040 |
Why?
|
| Antioxidants | 1 | 2001 | 564 | 0.040 |
Why?
|
| Cell Membrane | 3 | 2004 | 700 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 2017 | 438 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 275 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 849 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 305 | 0.040 |
Why?
|
| Insulin Glargine | 1 | 2017 | 73 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 444 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 210 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 135 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 527 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 298 | 0.040 |
Why?
|
| Phosphorus Radioisotopes | 2 | 1993 | 29 | 0.040 |
Why?
|
| Binding Sites | 1 | 2000 | 1221 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 701 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 377 | 0.040 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 41 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 871 | 0.030 |
Why?
|
| Estradiol | 1 | 2019 | 473 | 0.030 |
Why?
|
| Placenta | 1 | 2021 | 637 | 0.030 |
Why?
|
| Nitrendipine | 2 | 1993 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2000 | 725 | 0.030 |
Why?
|
| Collagen | 2 | 2009 | 433 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 269 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 251 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 5078 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 1995 | 35 | 0.030 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1995 | 8 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 226 | 0.030 |
Why?
|
| Heart Rate | 3 | 2009 | 729 | 0.030 |
Why?
|
| Lovastatin | 1 | 1995 | 27 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 347 | 0.030 |
Why?
|
| Glycogen | 1 | 1995 | 59 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 63 | 0.030 |
Why?
|
| Cystatin C | 1 | 2014 | 69 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1995 | 59 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1937 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 441 | 0.030 |
Why?
|
| Phosphorus | 1 | 2014 | 84 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2009 | 685 | 0.030 |
Why?
|
| Fatty Acid Synthases | 2 | 2006 | 29 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 27 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 394 | 0.030 |
Why?
|
| Lipolysis | 1 | 2013 | 42 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1993 | 45 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 125 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 163 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 59 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 683 | 0.030 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 67 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 923 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 770 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2013 | 73 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1806 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2007 | 304 | 0.030 |
Why?
|
| Optic Chiasm | 1 | 1992 | 18 | 0.030 |
Why?
|
| Colorado | 2 | 2017 | 4178 | 0.030 |
Why?
|
| Premenopause | 2 | 2003 | 107 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1992 | 30 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1338 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2004 | 572 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 283 | 0.030 |
Why?
|
| Physicians | 1 | 2020 | 792 | 0.030 |
Why?
|
| Thyrotropin | 1 | 1992 | 104 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 1992 | 68 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1992 | 51 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1302 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 725 | 0.020 |
Why?
|
| Potassium | 1 | 1991 | 132 | 0.020 |
Why?
|
| Headache | 1 | 1992 | 128 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1469 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1992 | 135 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1969 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 1992 | 165 | 0.020 |
Why?
|
| Inflammation | 3 | 2009 | 2545 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 191 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 402 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 214 | 0.020 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2009 | 52 | 0.020 |
Why?
|
| Plethysmography | 1 | 2009 | 124 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 562 | 0.020 |
Why?
|
| Swimming | 1 | 2009 | 46 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2009 | 65 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 354 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 252 | 0.020 |
Why?
|
| Hormones | 1 | 2009 | 135 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4684 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 143 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 187 | 0.020 |
Why?
|
| Myoglobin | 1 | 2007 | 15 | 0.020 |
Why?
|
| Betacellulin | 1 | 2007 | 7 | 0.020 |
Why?
|
| Fenofibrate | 1 | 2007 | 24 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1379 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4574 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 50 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 407 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 124 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 86 | 0.020 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Elastin | 1 | 2006 | 77 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 64 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2007 | 191 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 52 | 0.020 |
Why?
|
| Running | 1 | 2009 | 225 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 50 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 74 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 43 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 49 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2006 | 67 | 0.020 |
Why?
|
| Cadaver | 1 | 2007 | 327 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 65 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 6541 | 0.020 |
Why?
|
| Caspases | 1 | 2007 | 267 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 112 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 86 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2006 | 136 | 0.020 |
Why?
|
| RNA Stability | 1 | 2006 | 97 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 240 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2006 | 147 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 664 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 404 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 198 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 381 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2004 | 23 | 0.020 |
Why?
|
| Receptors, Odorant | 1 | 2004 | 36 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 40 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 3623 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 980 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 670 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 253 | 0.010 |
Why?
|
| Smell | 1 | 2004 | 118 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 302 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 857 | 0.010 |
Why?
|
| Serum Globulins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Imidazoles | 1 | 2003 | 227 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 652 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2002 | 74 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 967 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2001 | 20 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2001 | 38 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2002 | 150 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 8254 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 753 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 211 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1121 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 436 | 0.010 |
Why?
|
| Densitometry | 1 | 1998 | 30 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1998 | 66 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1986 | 1385 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 651 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1996 | 18 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 278 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 46 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1996 | 13 | 0.010 |
Why?
|
| Chromones | 1 | 1996 | 37 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 87 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 142 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 116 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 1996 | 71 | 0.010 |
Why?
|
| Smoking | 1 | 2003 | 1478 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 261 | 0.010 |
Why?
|
| Morpholines | 1 | 1996 | 106 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 1539 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1993 | 18 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1993 | 34 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1993 | 35 | 0.010 |
Why?
|
| Terpenes | 1 | 1993 | 23 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 380 | 0.010 |
Why?
|
| Neoplasms | 1 | 1986 | 2160 | 0.010 |
Why?
|
| Disulfiram | 1 | 1986 | 12 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1986 | 81 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1986 | 178 | 0.000 |
Why?
|
| Cisplatin | 1 | 1986 | 271 | 0.000 |
Why?
|